All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

(Reuters) -Drugmaker Pfizer posted a better than expected fourth quarter profit on Thursday, helped by cost cuts and a ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Pfizer's adjusted EPS of $0.63 surpassed the expected $0.47. Revenue reached $17.8 billion, exceeding the anticipated $17.35 ...

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...

For 2025, Pfizer forecast revenue between $61 billion and $64 billion, as well as adjusted earnings per share in the range of $2.80 to $3.00. Analysts polled by FactSet expect $63.07 billion in ...

Pfizer Inc (PFE) reports robust financial performance with significant revenue growth and strategic progress in oncology and ...

(Reuters) -Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors steadier execution and growth after ...

Pfizer swung to a fourth-quarter profit as revenue increased from a year earlier and came in better than some on Wall Street had predicted. The drugmaker logged net income of $410 million ...

Despite a significant year-over-year decline in Comirnaty revenue, the overall performance was strong, driven by growth in non-COVID-19 products and strategic acquisitions. Pfizer, a renowned ...